Terry Rosen - Arcus Biosciences Chairman
| RCUS Stock | USD 9.07 0.02 0.22% |
Chairman
Dr. Terry Rosen Ph.D., serves as Chairman of the Board, Chief Executive Officer, CoFounder of the company. He also served as the Chief Executive Officer of PACT Pharma, Inc., a biopharmaceutical company, from November 2016 to December 2017. Immediately prior to the founding of our company, Dr. Rosen served briefly in April 2015 as the Chief Executive Officer of FLX Bio, Inc., a biopharmaceutical company that was spunoff by Flexus Biosciences, Inc., a biopharmaceutical company. Previously, Dr. Rosen cofounded and served as the Chief Executive Officer of Flexus Biosciences, Inc. from October 2013 to April 2015, when it was acquired by BristolMyers Squibb. Prior to that, Dr. Rosen was at Amgen, Inc., a biopharmaceutical company, from 2004 to January 2013 where he most recently served as Vice President of Therapeutic Discovery from 2011 to January 2013. He also worked at Tularik Inc., a biopharmaceutical company, from 1993 to 2004 when it was acquired by Amgen, Pfizer Central Research, a biopharmaceutical company, from 1987 to 1993, and Abbott Laboratories, a health care company, from 1985 to 1987. Dr. Rosen serves on the board of trustees of the Salk Institute, the California Life Sciences Association and the Berkeley Foundation. He also serves on the boards of Ideaya Biosciences, Inc., PACT Pharma, Epiodyne, Inc. and Simcha Therapeutics Holding Company, LLC. Dr. Rosen also serves on the Scientific Advisory Board of Sirenas, LLC since 2017.
| Age | 65 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 3928 Point Eden Way, Hayward, CA, United States, 94545 |
| Phone | 510 694 6200 |
| Web | https://www.arcusbio.com |
Terry Rosen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Terry Rosen against Arcus Biosciences stock is an integral part of due diligence when investing in Arcus Biosciences. Terry Rosen insider activity provides valuable insight into whether Arcus Biosciences is net buyers or sellers over its current business cycle. Note, Arcus Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Arcus Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Terry Rosen over a year ago Acquisition by Terry Rosen of 100000 shares of Arcus Biosciences subject to Rule 16b-3 | ||
Terry Rosen over a year ago Exempt acquisition or disposition by Terry Rosen of 448 shares of Arcus Biosciences subject to Section 16 | ||
Terry Rosen over a year ago Disposition of 13705 shares by Terry Rosen of Arcus Biosciences subject to Rule 16b-3 | ||
Terry Rosen over a year ago Disposition of 8762 shares by Terry Rosen of Arcus Biosciences subject to Rule 16b-3 |
Arcus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1726) % which means that it has lost $0.1726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5977) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.37 in 2025. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 204.6 M in 2025, whereas Other Assets are likely to drop slightly above 8.5 M in 2025.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Allan Jacobson | PTC Therapeutics | 79 | |
| John CPA | Hepion Pharmaceuticals | 77 | |
| Richard MD | X4 Pharmaceuticals | 63 | |
| Douglas Treco | Inozyme Pharma | 67 | |
| Yves Sabbagh | Inozyme Pharma | N/A | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 |
Arcus Biosciences Leadership Team
Elected by the shareholders, the Arcus Biosciences' board of directors comprises two types of representatives: Arcus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcus. The board's role is to monitor Arcus Biosciences' management team and ensure that shareholders' interests are well served. Arcus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer MBA, Chief Officer | ||
| Juan Jaen, President, Co-Founder, Director | ||
| Nicole Lambert, Director | ||
| Patrick Machado, Independent Director | ||
| Jason Barker, Vice President - Finance | ||
| Jennifer Jarrett, Chief Business and Financial Officer | ||
| Eric Matthews, Chief Officer | ||
| Michael Quigley, Director | ||
| Linda Higgins, Director | ||
| Alexander Azoy, VP Officer | ||
| Antoni Ribas, Independent Director | ||
| Holli Kolkey, Vice Communications | ||
| Carolyn JD, General Secretary | ||
| Katherine Bock, Vice Strategy | ||
| Andrew Perlman, Independent Director | ||
| Robert II, Principal CFO | ||
| Eric Hoefer, Chief Commercial Officer & Head of Business Development | ||
| Stephen Young, Senior Biology | ||
| Jonathan Yingling, Chief Officer | ||
| Terry Rosen, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Yvonne Gehring, Senior Operations | ||
| Alexander CPA, VP Officer | ||
| Robert Goeltz, Chief Financial Officer, Principal Financial and Accounting Officer | ||
| Yasunori Kaneko, Lead Independent Director | ||
| David Lacey, Independent Director | ||
| Kathryn Falberg, Independent Director | ||
| Carolyn Tang, General Counsel | ||
| Merdad Parsey, Director | ||
| Christopher Garcia, CoFounder Board | ||
| William Grossman, Chief Medical Officer | ||
| Pia Eaves, Vice Strategy |
Arcus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (3.96) % | ||||
| Current Valuation | 33.51 M | ||||
| Shares Outstanding | 105.84 M | ||||
| Shares Owned By Insiders | 5.51 % | ||||
| Shares Owned By Institutions | 83.48 % | ||||
| Number Of Shares Shorted | 6.88 M | ||||
| Price To Earning | 27.69 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.